Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision
- PMID: 11497353
Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision
Abstract
Fomivirsen (ISIS-2922, Vitravene) is an antisense 21 mer phosphorothioate oligonucleotide with sequence complementarity to the coding region of the major immediate-early gene of human cytomegalovirus (CMV). Developed by Isis Pharmaceuticals Inc, fomivirsen is the first antisense oligonucleotide to receive approval for licensing and is marketed by Novartis' CIBA Vision. Fomivirsen is administered by intravitreal injection to AIDS patients for the treatment of CMV-induced retinitis. In August 1998, the FDA approved the marketing of Vitravene for the local treatment of CMV retinitis [296420], [296780], and both European and Brazilian registration approval followed in the summer of 1999 [335238].
Similar articles
-
Fomivirsen approved for CMV retinitis.J Int Assoc Physicians AIDS Care. 1998 Oct;4(10):14-6. J Int Assoc Physicians AIDS Care. 1998. PMID: 11365956
-
Fomivirsen approved for CMV retinitis: first antisense drug.AIDS Treat News. 1998 Sep 4;(302):7. AIDS Treat News. 1998. PMID: 11365764
-
New CMV retinitis drug approved.Body Posit. 1998 Oct;11(10):10. Body Posit. 1998. PMID: 11365907
-
Fomivirsen.Drugs. 1999 Mar;57(3):375-80; discussion 381. doi: 10.2165/00003495-199957030-00010. Drugs. 1999. PMID: 10193689 Review.
-
ISIS-3521. Isis Pharmaceuticals.Curr Opin Investig Drugs. 2001 Oct;2(10):1454-61. Curr Opin Investig Drugs. 2001. PMID: 11890365 Review.
Cited by
-
The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer.Biol Proced Online. 2004;6:250-256. doi: 10.1251/bpo95. Epub 2004 Oct 25. Biol Proced Online. 2004. PMID: 15514699 Free PMC article.
-
Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.Molecules. 2022 Jan 15;27(2):536. doi: 10.3390/molecules27020536. Molecules. 2022. PMID: 35056851 Free PMC article. Review.
-
Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.J Ophthalmol. 2011;2011:531380. doi: 10.1155/2011/531380. Epub 2011 Jun 30. J Ophthalmol. 2011. PMID: 21785698 Free PMC article.
-
Delivery of nucleic acid therapeutics for cancer immunotherapy.Med Drug Discov. 2020 Jun;6:100023. doi: 10.1016/j.medidd.2020.100023. Epub 2020 Mar 24. Med Drug Discov. 2020. PMID: 34337382 Free PMC article.
-
Approved Antiviral Drugs over the Past 50 Years.Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi: 10.1128/CMR.00102-15. Clin Microbiol Rev. 2016. PMID: 27281742 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous